Evaluating Engagement Of Abbv-0805, An Anti-Alpha-Synuclein Monoclonal Antibody To Physiological And Pathological Forms Of Alpha-Synuclein For Phase 2 Dose Selection: A Pbpk Modeling And Simulation Approach